Related Experiment Video
Updated: Jul 19, 2026
10:29
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
Published on: November 12, 2010
39.9K
Device-Based Therapy for Resistant Hypertension: An Up-to-Date Review
Oussama Jami1,2, Youssef Tijani3, Aziz Et-Tahir4
1High School of Technology in Salé, Materials, Energy and Acoustics Team Rabat, Mohammed V University in Rabat, Rabat, Morocco. oussamajami@research.emi.ac.ma.
Summary
Resistant hypertension (RH) is often uncontrolled due to medication non-adherence and high sympathetic activity. Device-based therapies offer a promising non-pharmacological treatment option for RH patients, supported by clinical trials.
Area of Science:
- Cardiovascular Medicine
- Hypertension Research
- Medical Device Technology
Background:
- Hypertension is a primary risk factor for cardiovascular disease, morbidity, and mortality.
- Uncontrolled hypertension significantly worsens overall health outcomes.
- Persistent uncontrolled hypertension, or resistant hypertension (RH), is characterized by medication non-adherence and increased sympathetic activity.
Purpose of the Study:
- To review emerging non-pharmacological treatments for resistant hypertension (RH).
- To discuss device-based therapies for RH and supporting clinical trial evidence.
- To highlight the role of novel technologies in managing RH.
Main Methods:
- Literature review of recent non-pharmacological treatments for RH.
- Analysis of device-based RH therapy technologies and their clinical validation.
- Discussion of clinical trials supporting device-based approaches.
Main Results:
- Device-based approaches targeting RH show promise as a therapeutic option.
- Several studies and clinical trials support the efficacy of these novel therapies.
- Drug non-adherence and high sympathetic activity are identified as key contributors to RH.
Conclusions:
- Novel device-based therapies represent a promising avenue for managing resistant hypertension.
- Further research is needed to optimize RH system design.
- Increased availability of randomized controlled trials is crucial for future validation.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...